Skip to main content

Biomarkers of neurological diseases

Guest Editors:
Santiago Perez-Lloret: Pontifical Catholic University of Argentina, National Research Council of Argentina
Wen-Jun Tu: Chinese Academy of Medical Sciences & Peking Union Medical College, China

BMC Neurology announced a new Collection focused on biomarkers of neurological diseases.

This Collection aims to explore how research into associated biomarkers can contribute to our understanding, diagnosis, and management of neurological conditions that affect millions of people worldwide.

SDG logo smallThis collection supports and amplifies research related to SDG 3: Good Health & Well-Being.

Meet the Guest Editors

Back to top

Santiago Perez-Lloret: Pontifical Catholic University of Argentina, National Research Council of Argentina

Santiago Perez-Lloret is a leading expert in neurophysiology and neuropharmacology, with more than 130 papers published in international medical journals. After obtaining his MD and PhD at the University of Buenos Aires, he pursued master’s courses in pharmacoepidemiology, clinical pharmacology, and biostatistics at the Universities of Toulouse, Bordeaux, and Paris. Dr Perez-Lloret is an Assistant Professor of Neurophysiology at the Medicine School of the University of Buenos Aires and a Senior Researcher at the Catholic University of Argentina, National Research Council. He is also an Associate Editor of BMC Neurology and a member of the Evidence-Based Medicine Committee of the International Parkinson’s Disease and Movement Disorder Society (MDS).
 

Wen-Jun Tu: Chinese Academy of Medical Sciences & Peking Union Medical College, China

Dr Wen-Jun Tu mainly engages in the following fields: prevention, diagnosis, prognosis, and rehabilitation of cerebrovascular diseases; development of biological kits; and construction of cerebrovascular disease biobanks. The future of his work is mainly focused on clinical applications of brain-computer interfaces. He has published more than 50 recent SCI-indexed papers with over 2,000 citations. He is an Associate Editor of several medical titles, including BMC Neurology.

About the collection

BMC Neurology is now welcoming submissions to a new Collection on biomarkers of neurological diseases and their potential in understanding, diagnosing, and managing various neurological conditions that impact millions of lives worldwide.

Neurological diseases, such as stroke, Parkinson’s disease, and multiple sclerosis pose significant challenges to individuals, their families, and healthcare systems. These conditions remain a significant public health concern, and as such, effective diagnostic tools, prognostic indicators, and personalized treatment strategies are in high demand. Measurable molecules and substances known as biomarkers hold immense promise in fulfilling these needs.

In this Collection, we invite submissions of cutting-edge original research offering novel perspectives on the identification, validation, and utilization of biomarkers in neurological diseases. We seek contributions that span a broad spectrum of disciplines, including genomics, proteomics, epidemiology, metabolomics, and transcriptomics. By embracing the synergistic power of these fields, we can harness the potential of biomarkers and grow closer to implementing them in clinical contexts.

Topics of interest to this Collection include, but are not limited to:

  •  Novel biomarkers for early detection and diagnosis of stroke, Parkinson’s disease, multiple sclerosis, or other neurological diseases
  •  Advancements in MRI, PET, or CT-based imaging biomarkers for neurologic disease detection and monitoring
  •  Using inflammatory markers as predictors of neurological disease progression and severity
  •  Oxidative stress as an indicator of neurodegeneration and potential targets for treatment response
  •  Using neurofilament proteins, tau protein, alpha-synuclein, and myelin-specific markers to diagnose the neuronal damage, degeneration, and myelin integrity associated with various neurological diseases
  •  The role of non-invasive biomarkers in neurology, such as blood-based or cerebrospinal fluid (CSF) biomarkers
  •  Challenges and opportunities in translating biomarker research to clinical practice


Image credit: Shidlovski / Getty Images / iStock

  1. Complex interactions between the immune system and the brain may affect neural development, survival, and function, with etiological and therapeutic implications for neurodegenerative diseases. However, previo...

    Authors: Min Shen, Linlin Zhang, Chen Chen, Xiaocen Wei, Yuning Ma and Yuxia Ma
    Citation: BMC Neurology 2024 24:98
  2. Human prion diseases (HPDs) are fatal neurodegenerative disorders characterized by abnormal prion proteins (PrPSc). However, the detection of prion seeding activity in patients with high sensitivity remains ch...

    Authors: Toshiaki Nonaka, Yasushi Iwasaki, Hiroyuki Horiuchi and Katsuya Satoh
    Citation: BMC Neurology 2024 24:92
  3. The global prevalence of VCI has increased steadily in recent years, but diagnostic biomarkers for VCI in patients with non-disabling ischemic cerebrovascular incidents (NICE) remain indefinite. The primary ob...

    Authors: Binghan Li, Zhengsheng Gu, Weisen Wang, Bingying Du, Chenghao Wu, Bin Li, Tianren Wang, Ge Yin, Xin Gao, Jingjing Chen, Xiaoying Bi, Hailing Zhang and Xu Sun
    Citation: BMC Neurology 2024 24:86
  4. CADASIL(Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)is an inherited small vessel disease caused by mutations in NOTCH3 gene. Although NOTCH3 has numerous hotspots...

    Authors: Weili Liu, Jie Zhang, Jian Li, Shuai Jia, Yanqiang Wang, Jianhong Geng and Yaozhen Wang
    Citation: BMC Neurology 2024 24:77
  5. Little is known regarding the leading risk factors for dementia/Alzheimer’s disease (AD) in individuals with and without APOE4. The identification of key risk factors for dementia/Alzheimer’s disease (AD) in i...

    Authors: Siting Ye, Eddy Roccati, Wei Wang, Zhuoting Zhu, Katerina Kiburg, Yu Huang, Xueli Zhang, Xiayin Zhang, Jiahao Liu, Shulin Tang, Yijun Hu, Zongyuan Ge, Honghua Yu, Mingguang He and Xianwen Shang
    Citation: BMC Neurology 2024 24:71
  6. Identification of the causes of stroke of undetermined etiology, specifically cardioembolism (CE) and non-CE causes, can inform treatment planning and prognosis prediction. The objective of this study was to a...

    Authors: Yi Jiang, Zhichao Sun, Zhonglin Ge, Zhonghai Tao, Mengqian Liu, Wen Zhong, Nan Dong, Lei Xu, Hui Wang, Yiwen Xu and Xiaozhu Shen
    Citation: BMC Neurology 2024 24:70
  7. Objective assessment of post-COVID-19 cognitive dysfunction is highly warranted. This study aimed to evaluate the cognitive dysfunction of COVID-19 survivors with cognitive complaints, both clinically and neur...

    Authors: Manal M. Gaber, Hanan Hosny, Mona Hussein, Mona A. Ashmawy and Rehab Magdy
    Citation: BMC Neurology 2024 24:60
  8. Status epilepticus (SE) is a severe acute condition in neurocritical care with high mortality. Searching for risk factors affecting the prognosis in SE remains a significant issue. The primary study’s aim was ...

    Authors: Zdenek Krejzar, David Sila, Petr Waldauf, Eduard Kuriscak, Petr Mokrejs and Vera Spatenkova
    Citation: BMC Neurology 2024 24:46
  9. There is often a fear of social stigma experienced by people with multiple sclerosis (pwMS), which negatively impacts the quality of their lives (QoL). Currently, no Persian-validated questionnaire is availabl...

    Authors: Mohammad Amin Habibi, Mohammad Yazdan Panah, Saeed Vaheb, Meysam Olfatifar, Aysa Shaygannejad, Yousef Mokary, Majid Ghasemi, Sangharsha Thapa, Vahid Shaygannejad and Omid Mirmosayyeb
    Citation: BMC Neurology 2024 24:36
  10. Myasthenia gravis (MG) is an autoimmune disease that affects neuromuscular junction. The literature suggests the involvement of circulating cytokines (CK), gut microbiota (GM), and serum metabolites (SM) with ...

    Authors: Wenwen Wang, Wei Ge, Junling Feng, Manli Huang, Xihua Zhang, Jielai Xia, Ling Wang and Chen Li
    Citation: BMC Neurology 2024 24:33
  11. Inflammation is a major pathological mechanism underlying cerebrovascular disease. Recently, a new inflammatory marker based on the ratio between monocyte count and high-density lipoprotein (HDL) cholesterol h...

    Authors: Ki-Woong Nam, Hyung-Min Kwon, Han-Yeong Jeong, Jin-Ho Park and Kyungha Min
    Citation: BMC Neurology 2024 24:18
  12. Stress hyperglycemia is a relatively transient increase in blood glucose in response to inflammation of the body and neurohormonal disorders. It is still debated whether stress hyperglycemia ratio (SHR) in the...

    Authors: Zhuoya Jiang, Kunyu Wang, Hanying Duan, Heqian Du, Su Gao, Jing Chen and Shaokuan Fang
    Citation: BMC Neurology 2024 24:13
  13. Thrombosis of dural sinuses and/or cerebral veins (CVT) is an uncommon form of cerebrovascular disease. Malnutrition is common in patients with cerebrovascular disease, and early assessment of malnutrition and...

    Authors: Weiwei Xiang, Yangyang Liang, Zhibo Chen, Hanmin Wang, Yangtai Guan and Dewei Xie
    Citation: BMC Neurology 2023 23:449
  14. Multiple inflammatory biomarkers have been shown to predict symptomatic cerebral vasospasm (SCVS) and poor functional outcome in patients with aneurysmal subarachnoid hemorrhage. However, the impact of the low...

    Authors: Ling wang, Ling Chen, Yang Jin, Xiangyang Cao, Liujun Xue and Qiantao Cheng
    Citation: BMC Neurology 2023 23:436
  15. Trimethylamine-N-oxide (TMAO), an intestinal microbiota-derived choline metabolite, has been found to be associated with ischemic stroke (IS) in more and more studies. However, the causal role of TMAO on IS oc...

    Authors: Xinhua Hu, Haiyan Ren and Yuan Cao
    Citation: BMC Neurology 2023 23:413
  16. A Phase I study showed that it is feasible to implement a home-based self-management program aimed at increasing physical activity in individuals after stroke with mild walking disability in Brazil. The next s...

    Authors: Maria Tereza Mota Alvarenga, Louise Ada, Elisabeth Preston, Lívia Cristina Guimarães Caetano, Luci Fuscaldi Teixeira-Salmela and Aline A Scianni
    Citation: BMC Neurology 2023 23:412

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Biomarkers of neurological diseases" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.